Phase III placebo-controlled trial of PSD502 in primary premature ejaculation in China

Phase 3, randomised, double-blind trial of lidocaine + prilocaine in premature ejaculation (PE) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Change in mean intravaginal ejaculatory latency time from baseline to during the 3 months of double-blind treatment, Change in Index of Premature Ejaculation ejaculatory control domain from baseline to month 3 and 2 more. Started Dec 2021; status: completed.